Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single Arm Open Label Study of Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer: an EMBRACE High Risk Study Initiative

NCT07368985 is registered in ClinicalTrials.gov with Prof. Dr. Remi A. Nout as lead sponsor.

NCT NCT07368985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07368985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single Arm Open Label Study of Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer: an EMBRACE High Risk Study Initiative
Lead sponsor
Prof. Dr. Remi A. Nout
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2026
Completion date
October 31, 2029
Enrollment
87 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma or adeno-squamous carcinoma stage ib3-iiic2, cervical cancer by figo stage 2018, squamous cell carcinoma figo 2018 stage iiia, iiib, iiic1-iiic2